Search Results - entry

2 Results

Sort By:

COMBINATION THERAPIES FOR COVID-19 (SARS-COV-2)

The coronavirus disease 2019 (COVID-19) is caused by a novel RNA enveloped coronavirus, SARS-CoV-2 when the virus enters human airway cells via an ACE2-mediated entry process. This entry pathway is facilitated by the cell surface heparan sulfate proteoglycan (HSPG), which enhances viral attachment to the cell surface. Researchers at NIDDK and NCATS...

Published: 7/25/2024 | Inventor(s): Qi Zhang, Wei Zheng, Catherine Chen, Yihong Ye

Keywords(s): COVID-19, DB4BXX, ENTRY, HEPARAN, option, Sulfate-dependent, Targeting, therapeutic, viral

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics

Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development

Many members of the Flaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated...

Published: 7/25/2024 | Inventor(s): Konstantin Tsetsarkin, Alexander Pletnev

Keywords(s): Approach, ATTENUATION, DC1XXX, DC5BXX, DC5XXX, DC6XXX, DCXXXX, DD1XXX, DDXXXX, Development, DEXXXX, DXXXXX, ENTRY, FLAVIVIRUSES, INTERNAL, Live, Pnd, RIBOSOME, Site/microRNA-based, Synergistic, Vaccine, Zika

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Research Materials, Application > Vaccines